From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was grandly held in Orlando, USA. As the world’s largest and most influential international academic conference in the field of hematology, the ASH Annual Meeting attracts tens of thousands of experts and scholars each year to share the latest advances and breakthrough research. At this year’s meeting, a study led by Professor Sun Ruijuan from Lu Daopei Hospital was selected for poster presentation, focusing on the clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia, providing important insights for the treatment of this challenging patient population. Hematology Frontier invited Professor Sun to share the details of this study for academic exchange.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, showcasing the latest global advances in hematology. Multiple studies…

From December 6–9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together leading experts worldwide to present the latest breakthroughs in…

Previous collaborative studies between the European Society for Blood and Marrow Transplantation (EBMT) and Prof. He Huang’s team have demonstrated that haploidentical hematopoietic stem cell transplantation (HAPLO-HSCT) can confer clinical…

At the 67th Annual Meeting of the American Society of Hematology (ASH), Prof. Ou Bai and her team from The First Hospital of Jilin University presented multiple impactful studies. Two…

The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, bringing together the latest global advances in hematologic research and clinical practice. At this year’s meeting, four studies led by Prof. Yajing Zhang from Beijing Gobroad Boren Hospital were accepted, including one oral presentation.

In recent years, with the rapid development of precision genomics, hereditary predisposition genes have gained increasing attention for their clinical value in the diagnosis and treatment of hematologic malignancies. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Li Zhihui from Beijing Gaobo Boren Hospital was selected for oral presentation, systematically evaluating the impact of hereditary predisposition genes on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and donor selection. Hematology Frontier invited Professor Li for an in-depth interpretation of this study and its implications for clinical practice.